Cargando…

Lesinurad: what the nephrologist should know

Lesinurad is an oral inhibitor of the monocarboxylic/urate transporter URAT1 encoded by the SLC22A12 gene. Market authorization was granted in February 2016 in Europe and December 2015 in the USA. As a potentially nephrotoxic uricosuric drug acting on the kidney, nephrologists should become familiar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanchez-Niño, Maria Dolores, Zheng-Lin, Binbin, Valiño-Rivas, Lara, Sanz, Ana Belen, Ramos, Adrian Mario, Luño, Jose, Goicoechea, Marian, Ortiz, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Cardiovascular Risk
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622894/ https://www.ncbi.nlm.nih.gov/pubmed/28979780 http://dx.doi.org/10.1093/ckj/sfx036

Ejemplares similares

Central Venous Stenosis: What Should a Nephrologist Know?
por: Mehta, H. J.
Publicado: (2017)

Obesity and chronic kidney disease: what should pediatric nephrologists know?
por: Lee, Jung Won
Publicado: (2021)

What happens after the kidney biopsy? The findings nephrologists should know
por: Montes, Daniel, et al.
Publicado: (2022)

CD74 in Kidney Disease
por: Valiño-Rivas, Lara, et al.
Publicado: (2015)

Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes
por: Cuarental, Leticia, et al.
Publicado: (2020)

Relationship between flow-mediated vasodilation and cardiovascular risk factors in a large community-based study
por: Maruhashi, Tatsuya, et al.
Publicado: (2013)

A clinical-genetic approach to assessing cardiovascular risk in patients with CKD
por: Rodrigo, Emilio, et al.
Publicado: (2017)

Association between normal or mildly reduced kidney function, cardiovascular risk and biomarkers for atherosclerosis: results from the ENCORE trial
por: Tyson, Crystal C., et al.
Publicado: (2017)

A cardiovascular risk prediction model for older people: Development and validation in a primary care population
por: van Bussel, Emma F., et al.
Publicado: (2019)

Consequences of access to water from managed aquifer recharge systems for blood pressure and proteinuria in south-west coastal Bangladesh: a stepped-wedge cluster-randomized trial
por: Naser, Abu Mohd, et al.
Publicado: (2020)

High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease
por: Zuber, Verena, et al.
Publicado: (2020)

Commentary: Big data bring big controversies: HDL cholesterol and mortality
por: Ala-Korpela, Mika, et al.
Publicado: (2021)

Statin-related Muscle Toxicity: An Evidence-based Review
por: Jeeyavudeen, Mohammad S, et al.
Publicado: (2022)

Association between office visit intervals and long‐term cardiovascular risk in hypertensive patients
por: Kim, Duon, et al.
Publicado: (2023)

Role of fructosamine-3-kinase in protecting against the onset of microvascular and macrovascular complications in patients with T2DM
por: Sartore, Giovanni, et al.
Publicado: (2020)

Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout
por: Pérez-Ruiz, Fernando, et al.
Publicado: (2019)

SARS-CoV-2 Infection Evolution Among Nephrologists During the Pandemic: Clinical Features and Impact of Vaccination
por: Quiroga, Borja, et al.
Publicado: (2022)

Any grade of relative overhydration is associated with long-term mortality in patients with Stages 4 and 5 non-dialysis chronic kidney disease
por: Vega, Almudena, et al.
Publicado: (2018)

Ideal Cardiovascular Health and the Prevalence and Progression of Coronary Artery Calcification in Adults With and Without Type 1 Diabetes
por: Alman, Amy C., et al.
Publicado: (2014)

Coronary Artery Calcification in Obese Youth: What Are the Phenotypic and Metabolic Determinants?
por: Bacha, Fida, et al.
Publicado: (2014)

Podocyturia: why it may have added value in rare diseases
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2018)

The development of an effective synthetic route of lesinurad (RDEA594)
por: Meng, Qing, et al.
Publicado: (2017)

Glycemic variability and cardiovascular disease in patients with type 2 diabetes
por: Martinez, Marcela, et al.
Publicado: (2021)

TWEAK increases CD74 expression and sensitizes to DDT proinflammatory actions in tubular cells
por: Valiño-Rivas, Lara, et al.
Publicado: (2018)

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
por: Lomonaco, Romina, et al.
Publicado: (2016)

Heparin-induced thrombocytopaenia (HIT)—an overview: what does the nephrologist need to know and do?
por: Dutt, Tina, et al.
Publicado: (2013)

Levels of ankle–brachial index and the risk of diabetes mellitus complications
por: Alves-Cabratosa, Lia, et al.
Publicado: (2020)

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers
por: Gillen, Michael, et al.
Publicado: (2016)

Patient considerations in the management of gout and role of combination treatment with lesinurad
por: Claus, Liza W, et al.
Publicado: (2018)

Maternal Cardiac Changes in Women With Obesity and Gestational Diabetes Mellitus
por: Thirunavukarasu, Sharmaine, et al.
Publicado: (2022)

Diabetes and infectious disease mortality in Mexico City
por: Bragg, Fiona, et al.
Publicado: (2023)

The new marker YKL-40, a molecule related to inflammation, is associated with cardiovascular events in stable haemodialysis patients
por: Vega, Almudena, et al.
Publicado: (2019)

Non-canonical NFκB activation promotes chemokine expression in podocytes
por: Valiño-Rivas, Lara, et al.
Publicado: (2016)

Endodontic Rotary Files, What Should an Endodontist Know?
por: Dablanca-Blanco, Ana-Belén, et al.
Publicado: (2022)

What Patients Should Know
por: Bigelow, A. T.
Publicado: (1899)

Determination of lesinurad in rat plasma by a UHPLC–MS/MS assay
por: Zhou, Xiao-Yang, et al.
Publicado: (2017)

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019)

Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor Therapy
por: Perez-Ruiz, Fernando, et al.
Publicado: (2019)

COVID-19 vaccination among Spanish nephrologists: Acceptance and side effects
por: Quiroga, B., et al.
Publicado: (2021)

Nurofen Plus toxicity—what should nephrologists be alert to? Rare complications of an increasingly misused medication
por: Medani, Samar, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_c26lj72i95l0lhvde26s3ue1mn